Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Gains from Investment Securities (2022 - 2025)

TriSalus Life Sciences' Gains from Investment Securities history spans 4 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 122.03% year-over-year to $2.5 million; the TTM value through Dec 2025 reached -$754000.0, up 97.24%, while the annual FY2025 figure was $66000.0, 100.59% up from the prior year.
  • Gains from Investment Securities reached $2.5 million in Q4 2025 per TLSIW's latest filing, up from -$2.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.8 million in Q3 2022 to a low of -$19.9 million in Q3 2023.
  • Average Gains from Investment Securities over 4 years is -$3.4 million, with a median of -$700000.0 recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: surged 149.15% in 2023, then plummeted 7727.89% in 2024.
  • A 4-year view of Gains from Investment Securities shows it stood at $59000.0 in 2022, then soared by 149.15% to $147000.0 in 2023, then tumbled by 7727.89% to -$11.2 million in 2024, then skyrocketed by 122.03% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Gains from Investment Securities are $2.5 million (Q4 2025), -$2.5 million (Q3 2025), and -$700000.0 (Q2 2025).